New hope for bladder cancer patients who Can't take chemo
NCT ID NCT03601455
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining radiation therapy with immunotherapy drugs (durvalumab with or without tremelimumab) can help people with advanced bladder cancer who cannot or will not have chemotherapy. The trial includes 13 participants with cancer that has spread or cannot be removed by surgery. Researchers are checking for side effects and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Durvalumab (Imfinzi) and tremelimumab, both immunotherapy drugs, plus external beam radiation therapy
- What this could lead to
- If it works, this could offer a chemotherapy-free treatment option for advanced bladder cancer, potentially controlling the disease for longer.
- What could go wrong
- This is a small, early-phase trial (13 participants) focused on safety and progression-free survival. The combination may not work better than standard care, and side effects from immunotherapy and radiation can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bladder cancer: a new combo aims to avoid radical surgery
- Can a targeted antibody-drug combo tackle rare bladder cancers?
- Bladder cancer breakthrough? new combo aims to save the bladder
- New cocktail of drugs takes on Hard-to-Treat bladder cancer
- New strategy aims to eliminate residual bladder cancer after drug combo
- Experimental triple therapy for advanced cancers shows early promise but trial halted